Testosterone Undecanoate for Women: The Definitive Guide

What is testosterone undecanoate in women’s care?

Testosterone undecanoate (TU) is an ester form of testosterone used in some oral capsules and long-acting injections. The ester changes delivery and release; it is not the same amount or product as a testosterone cream. In women’s menopausal care, oral TU remains a research question rather than an established labeled replacement regimen in the products reviewed here. [1], [2], [3], [5]

Testosterone can have an evidence-based role for hypoactive sexual desire disorder (HSDD) after a clinical assessment. HSDD describes persistently low sexual desire causing personal distress, not merely a low laboratory number or less frequent sex. The best-supported recommendations favor physiological transdermal treatment; ISSWSH does not recommend oral formulations. Evidence about testosterone generally cannot establish a safe TU capsule dose. [4]

Current US Kyzatrex labeling explicitly says it is not indicated for women. A small older trial, a proposed registered pilot and a 2026 bioequivalence study are useful to understand the research, but none creates a standard female maintenance prescription. The table below identifies research amounts so they cannot be mistaken for a suggested starting dose. [1], [2], [3], [5]

Typical Testosterone Undecanoate Protocols: Women’s Research Context

No ordinary female oral-TU prescribing pattern is established here. Every numeric row is an explicitly identified study or registered proposal, retaining product, route, population, food context and duration. Clinical testosterone guidance supports assessed HSDD and physiological exposure, generally transdermal; it does not license copying male oral/injectable amounts. A 2015 result or a 2026 bioequivalence finding cannot set a titration calendar. Follow-up and safety must come from the actual appropriate product/guideline or approved research protocol. [1], [2], [3], [4], [5]

Which clinical problem has evidence for testosterone?

The evidence-based target is distressing low desire assessed in its biological, psychological and relationship context. Painful sex, vaginal symptoms, depression/anxiety, medication effects, relationship difficulties, fatigue and untreated vasomotor symptoms can contribute. Identifying these does not dismiss the symptom; it helps choose a useful intervention and avoid attributing every problem to one hormone. [4]

NICE recommends considering testosterone for menopause-associated low sexual desire when HRT alone is ineffective. Its August 2026 minor update reinstated an off-label note that had been removed in error. That recommendation is named guidance, not approval of oral TU or an instruction to treat muscle gain, weight, cognition, general energy or a serum target. [6], [8]

The current UK AndroFeme cream SmPC is an example of a separately authorized female product: postmenopausal HSDD on optimized HRT, following assessment of treatable causes. Its starting applied amount is 0.5 mL containing 5 mg testosterone daily. Applied cream amount is different from absorbed hormone and different from a TU capsule. This newer authorization also makes the blanket claim “no UK testosterone is licensed for women” outdated. [7]

A person with low desire but no distress, or a low lab result without that clinical problem, does not automatically have HSDD. Nor does estrogen failure alone identify an oral-TU candidate. The aim is meaningful improvement in desire/distress with appropriate exposure and safety review, not reproducing male replacement physiology. [4], [6]

Why can a male dose or cream amount not be converted?

Routes and formulations determine absorption. An oral TU capsule, a transdermal cream and a long-acting TU injection can contain very different masses while producing different blood exposure. A one-tenth male-transdermal-dose guideline example does not authorize one-tenth of an oral capsule, a depot injection or another product’s weekly amount. [1], [4]

Food-dependent oral absorption also matters. The studies specify the capsule formulation, meal context and sampling schedule. Newer capsule formulations should not be assumed identical to older Andriol-type products, and a cream’s applied milligrams do not give the same absorbed testosterone as oral ester milligrams. There is no validated conversion table for these women’s TU regimens in the reviewed guidance. [1], [2], [4], [5]

The registered 50 mg pilot amount is investigational. The current retrieved Kyzatrex label lists marketed 100, 150 and 200 mg strengths, while the registry describes a 50 mg study capsule. The registry does not certify today’s commercial availability of that strength, and a larger soft capsule should not be opened or divided to manufacture it. The differing records remain explicit rather than silently resolved by arithmetic. [1], [3]

A long-acting injection cannot be quickly withdrawn after an unwanted effect, and ISSWSH does not recommend intramuscular preparations for this purpose. This matters when exposure exceeds the physiological female range or androgenic effects emerge. A preference to avoid daily application does not itself establish a safer alternative delivery route. [4]

What does “oral testosterone” actually mean?

The phrase can describe TU capsules, older alkylated androgens, compounded dissolving troches or another oral product. These are not interchangeable identities. A lozenge that partly dissolves in the mouth can also be swallowed, and ISSWSH considers compounded troches/buccal preparations in its oral-formulation discussion. A forum report about “oral T” cannot be assumed to concern TU. [1], [4], [9], [10]

TU is processed into testosterone after absorption. Its formulation can reduce the particular first-pass issues of older methylated oral androgens, but that does not establish zero liver or cardiovascular risk, stable female physiological exposure, or long-term HSDD safety. “Not the old oral steroid” is a chemical distinction, not a complete safety conclusion. [1], [4], [5]

For a research protocol, its investigator specifies the product, meal, dose, visits and safety plan. For ordinary care, the clinician should identify an evidence-supported and locally appropriate formulation rather than borrowing a trial calendar. Do not replace a cream with capsules, combine multiple testosterone routes or assume the same lab-sampling timing works for each. [4], [7]

What should the product record contain?

The current Kyzatrex label gives 20–25°C storage with permitted 15–30°C excursions, in a dry place avoiding excessive moisture. These are that product’s instructions, not authorization for its use in women. A different study capsule, cream or injection has its own storage directions. Keep the actual product and strength identified. [1]

Record indication, route, full formulation, amount actually used, timing with food if relevant, laboratory sampling time and any other hormones. Keep research-only quantities clearly separate from an ordinary prescription record. A compounded capsule or lozenge also needs its exact formulation rather than the generic label “testosterone.” [1], [3], [4]

A source listing, a pilot registration or another person’s pharmacy access does not guarantee a verified female product. Avoid creating a smaller amount from a male soft capsule or obtaining an unverified formulation to match a study number. The practical next step is product-specific clinical review, not a home conversion. [1], [4]

What do the three kinds of TU study establish?

The 2015 randomized double-blind trial assigned 70 postmenopausal women with sexual complaints and a low Female Sexual Function Index (FSFI) score to oral TU or placebo, 35 per group. Both groups also received daily oral estrogen. TU was 40 mg twice weekly for eight weeks. One participant in the TU group was lost to follow-up. [2]

Both groups improved from baseline. At eight weeks, mean total FSFI scores were 28.6 ± 3.6 with TU versus 25.3 ± 6.7 with placebo plus estrogen, with p=0.04. The questionnaire combines several aspects of sexual function; this is not a percentage of participants whose HSDD resolved. The sample and follow-up could not establish rare adverse-event or long-term breast/endometrial safety. [2]

NCT06082817 describes an open-label, single-group pilot proposal, estimated enrollment 30, studying pharmacokinetics and safety of a 50 mg daily oral TU capsule over three months. A registered dose is not a result. The retrieved record retains projected dates and a not-yet-recruiting status; no outcome report was reviewed. It also has inconsistent testosterone units/criteria in different sections, so those numbers are not reproduced as a clinical diagnostic threshold. [3]

The March 2026 bioequivalence study enrolled 48 healthy postmenopausal Chinese women. Participants received single 40 mg doses in a four-period crossover comparing a test capsule with Andriol Testocaps after food. All completed the trial. It showed the prespecified pharmacokinetic bioequivalence criteria were met, not that either product improved HSDD or was safe as long-term daily therapy. The investigators identify the difference between these healthy participants and the male target-treatment population. [5]

A short trial without detected differences in selected safety measures does not prove no risk. Likewise, bioequivalence means similar exposure under the study conditions, not equivalent clinical benefit in a new indication. The guideline preference for physiological transdermal treatment and the current TU product’s lack of a female indication remain unchanged by these limited studies. [1], [4], [5]

How do the ester and blood measurements relate?

TU’s ester supports formulation-specific delivery; hydrolysis releases testosterone, which acts through androgen receptors and can be converted to dihydrotestosterone or estrogen in tissues. The amount printed on a capsule is an ester mass, not a measured amount absorbed each day by a particular woman. Food and formulation affect the exposure profile. [1], [5]

A serum testosterone value helps avoid excessive treatment exposure, but cannot diagnose the cause of low desire or identify one optimal value for everyone. ISSWSH recommends keeping exposure in the physiological premenopausal range rather than increasing doses to overcome a high SHBG value. SHBG is a binding protein that affects hormone availability; it is not permission to drive total testosterone above the reference range. [4]

The pharmacology also does not make testosterone a substitute for estrogen-related lining protection. If systemic estrogen continues with a uterus present, its separate protection plan remains necessary. Converting some testosterone to estrogen is not an established complete menopause regimen. [4], [6]

Which uncertainties and unwanted effects matter?

Excess androgen exposure can cause acne, unwanted hair growth, scalp hair loss and other virilizing effects. Voice deepening or clitoral changes may be difficult to reverse. A report of better energy does not justify continuing excessive levels or a worsening unwanted effect. Pregnancy exposure can harm a fetus; TU is not contraceptive treatment. [1], [4]

The current Kyzatrex label removed its boxed blood-pressure warning in July 2025, but still warns that blood pressure can increase. The removal does not establish cardiovascular safety for women. Its quantified blood-pressure findings and male monitoring/titration instructions should not be copied as female risk estimates or a women’s protocol. [1]

ISSWSH’s recommendation against oral testosterone considers formulation and short-term safety evidence. TU is chemically different from older alkylated androgens, yet this does not prove a particular female oral regimen is liver-safe or breast-safe. Long-term physiological-dose testosterone trial safety beyond 24 months remains limited in the guideline, and TU-specific maintenance evidence is thinner. [1], [4], [5]

Personal breast-cancer history, liver disease, lipid abnormalities, cardiovascular risk, pregnancy possibility and interacting medicines require a product-specific clinical discussion. Severe new chest pain, breathlessness, one-sided weakness, major mood deterioration, jaundice or other serious effects require prompt assessment. A trial’s exclusion criteria are not an exhaustive ordinary-care checklist or evidence of safety outside that selected group. [1], [2], [4]

Avoid stacking routes, using a male depot schedule or treating above-range blood results as an expected adaptation phase. Monitor symptoms and levels with the clinician; discontinue or change a regimen when clinically required. A previous positive response or a favorable forum account cannot settle long-term risk. [4]

What is verified, approved or still investigational?

The reviewed US oral TU label is for male treatment, explicitly not indicated in women. The UK now has a separate female AndroFeme cream authorization, while NICE’s recommendation retains its named off-label note. These facts describe different products and frameworks; none certifies an approved UK or US oral TU menopause schedule. [1], [6], [7], [8]

Research registration is also separate from recruitment, results and pharmacy supply. The returned NCT record has old projected dates, so it does not establish that enrollment is currently open or that the pilot was completed. A current sponsor/registry confirmation is needed before making a live research-access claim. This guide does not direct readers into an unverified study or infer clinical availability from it. [3]

Outside those reviewed sources, current national authorization, marketing and reimbursement need their own checks. A male approved medicine can be discussed off-label clinically without becoming an approved female product; approval of a topical female formulation does not extend to oral TU. Keep exact country, indication and product on an access request. [1], [4], [7]

What do public oral-testosterone discussions clarify?

A 2025 women’s public discussion asks whether a male relative’s oral product applies to menopause. Replies mix Kyzatrex, compounded troches and other formulations, with favorable experiences, little benefit and concerns about liver measures. This shows a real need for product identity, not a verified female TU response rate or a safe-dose calculation. [9]

Another thread discusses dissolving lozenges, uncertain mood attribution, irritability and hair concerns, while some contributors describe a preference for another route. Those reports are not automatically TU capsule experiences. Claims that every oral product is identical, that a troche bypasses all swallowed exposure, or that no previous patient had a changed liver test do not replace the actual label and guideline. [4], [10]

Only public text was reviewed; no names, identifiable histories or numerical satisfaction claims are retained. The retrieved material did not establish a reliable female TU-specific community cohort. Use it to prepare questions about formulation, the clinical goal, unwanted androgen effects and why a route was chosen, while keeping improvement and nonresponse visible without promising either. [9], [10]

What should be monitored?

For appropriate testosterone treatment, track the indication, exact product/route, actual amount, symptom goals and unwanted effects. Baseline total testosterone and SHBG help avoid starting with excessive exposure; ISSWSH also recommends baseline liver function and fasting lipids. A lab value is not the diagnosis of HSDD. [4]

ISSWSH recommends total testosterone reassessment three to six weeks after starting, within six weeks of a dose increase, and every four to six months after levels stabilize. The purpose is avoiding excessive exposure rather than chasing a universal target. Different formulations have different pharmacokinetics, so the sample timing and interpretation need the actual product and clinical plan. [4]

Assess acne, unwanted hair, scalp hair loss and meaningful changes in desire/distress. An above-range value warrants dose review even without obvious androgen effects. If exposure is reduced for excess, the guideline describes an earlier recheck after two to three weeks. It does not authorize oral TU or supply a TU-specific titration algorithm. [4]

AndroFeme’s UK label has its own follow-up and six-month monitoring instructions; a research protocol has its own visits and sampling. These cannot simply be combined into one calendar. Keep any estrogen/progestogen regimen separately visible and continue appropriate national screening and assessment of unexpected bleeding. [4], [7]

What happens when treatment stops?

If clinically meaningful benefit is absent, ISSWSH recommends not continuing testosterone beyond six months and reassessing causes of low desire. Troublesome effects or excessive exposure can require earlier change. This is guidance for appropriate testosterone care, not a six-month permission to try an unestablished TU regimen. [4]

The decision to stop uses the actual formulation. Daily transdermal treatment and a long-acting depot have different persistence; an injection cannot be removed after administration. No universal capsule-splitting, taper or male depot schedule is recommended here. Discuss the last actual dose and any other testosterone or hormones being used. [1], [4]

Stopping testosterone does not automatically stop estrogen, vaginal therapy or endometrial protection. If systemic estrogen continues with a uterus present, that separate plan remains important. New serious adverse effects or virilizing changes should be assessed promptly rather than waiting for an online adaptation period. [4], [6]

How does it compare with other options?

Transdermal testosterone has the strongest guideline-supported role for assessed HSDD in women, with physiological exposure and monitoring. A labeled female cream, an off-label male transdermal product, an investigational oral TU capsule and a compounded lozenge are distinct products with different evidence and authorization. No head-to-head superiority is inferred from different studies. [4], [7]

Vaginal prasterone treats a different local clinical problem; systemic DHEA is not a proven interchangeable HSDD substitute. Estrogen and local vaginal treatment may address pain, dryness or other contributors, while psychosocial or medication-related causes need their own interventions. A treatment comparison begins with the actual problem and relevant population. [4], [6]

Female transdermal doses cannot be calculated from male oral or injected TU schedules. Likewise, a trial’s ester mass cannot be compared with the amount of testosterone applied in cream. The clinical testosterone hub explains the wider indication and alternatives; this page retains the specific TU uncertainty. [1], [4], [7]

Common questions

Does a low blood result mean I need TU?

No testosterone threshold diagnoses HSDD. Desire, distress, pain, mood, medication and relationship context require assessment. Levels help avoid excessive exposure if treatment is used; they do not establish an oral-TU indication or a universal target. The best-supported recommendations concern physiological transdermal treatment in an appropriate clinical population. [4] Keep the clinical diagnosis and the exposure check separate. An isolated laboratory number cannot identify every reason for low desire or justify a male oral product. See the clinical purpose. [4]

Can I split a male capsule to get the pilot dose?

No verified capsule-splitting regimen is supplied here. The pilot’s 50 mg is a proposed research formulation; the current reviewed Kyzatrex label lists 100, 150 and 200 mg strengths and is not indicated for women. A soft capsule cannot be assumed to provide equal smaller doses. Discuss an appropriate product instead of manufacturing an investigational amount. [1], [3], [4] The registered amount is a research proposal, not a verified compounding instruction. Product route and study status remain necessary parts of the claim. See the product schedules. [1] [3]

Does the 2026 study prove daily TU is safe?

It compared pharmacokinetic exposure after single 40 mg doses in 48 healthy postmenopausal women over a four-period crossover. It was not a daily HSDD efficacy trial or long-term safety study. Bioequivalence under its food/formulation conditions does not establish maintenance treatment benefit or exclude rare harms. [5] Food conditions and a single-dose comparison cannot answer the same question as repeated symptom treatment. Keep pharmacokinetics separate from clinical benefit and long-term risk. See the study evidence. [5]

Is it useful for muscle, brain fog or general energy?

Those goals are not established oral-TU indications in the reviewed women’s evidence. A positive anecdote cannot transfer the HSDD treatment evidence to general wellbeing or body composition. Assess the symptom and its causes, and use a clinically meaningful goal rather than a male replacement target. [4], [6] Different symptoms can require different assessments and treatments. A testimonial about energy does not establish the same indication, route or benefit as the HSDD evidence. See the treatment goals. [4] [6]

Can testosterone replace my estrogen or protection medicine?

Testosterone is not an established replacement for the whole menopausal regimen. It does not provide progestogen opposition to prescribed systemic estrogen. If estrogen continues with a uterus present, that separate protection plan still matters; a possible conversion of testosterone to estrogen is not a complete validated regimen. [4], [6] The clinician should review the whole treatment rather than counting one hormone as several components. The indication and protection requirements stay attached to the actual products. See the treatment comparisons. [4] [6]

When is no benefit a reason to stop?

ISSWSH recommends not continuing beyond six months without clinically meaningful improvement and reassessing contributing causes. That guideline is about appropriate testosterone treatment, not authorization to try oral TU for six months. Unwanted effects or excessive exposure can require earlier change or stopping. [4] A trial duration does not create a universal adjustment period. Review the meaningful goal, unwanted effects and the actual route when deciding whether continuation is justified. See the stopping considerations. [4]

Glossary

Terms used to read the product and evidence.

Adverse event

An unwanted event during treatment; it is not automatically caused by the medicine.

Amenorrhea

Absence of menstrual periods. Secondary amenorrhea occurs after periods have previously occurred.

Bioavailability

The amount of an administered medicine reaching the circulation; formulation and route can change it.

Bioidentical

Chemically identical to a hormone the body makes; the word does not establish safety or product quality.

Biopsy

A tissue sample examined for abnormalities, unlike an ultrasound measurement of thickness.

Boxed warning

A prominent warning format used in a medicine label; removing the box does not remove every risk.

Compounding

Preparing a medicine to a prescription rather than supplying a standard approved finished product.

Continuous combined HRT

Estrogen and progestogen used continuously according to their prescriptions, without scheduled progestogen-free days.

Contraindication

A condition in which a particular product must not be used under its label.

Cycle

A repeating treatment calendar. A 28-day cycle and a calendar month have different lengths.

Daily total

All doses taken on one day added together, not the average across days without treatment.

Endometrium

The lining inside the uterus that can grow in response to estrogen.

Estrogen

A family of hormones including estradiol; systemic treatment and low-dose local treatment have different purposes.

Excipient

An ingredient other than the active medicine, such as a capsule oil or lecithin.

First-pass metabolism

Processing in the intestine and liver before an oral medicine reaches the wider circulation.

Hormone replacement therapy (HRT)

In this guide, hormone treatment for menopause-related needs; also called menopausal hormone therapy.

Hyperplasia

Excessive tissue growth. Endometrial hyperplasia is not the same diagnosis as endometrial cancer.

Hysterectomy

Surgery removing the uterus; removal of ovaries is a different procedure.

Intrauterine device (IUD)

A device placed inside the uterus. Protection duration in HRT can differ from contraception duration.

Metabolite

A substance produced as the body processes another substance. Some progesterone metabolites affect brain signaling.

Micronization

Making particles smaller to change their dissolution and absorption, without changing the hormone molecule.

Milligram (mg)

A unit of mass; a 100 mg capsule contains 100 milligrams of active progesterone.

Observational study

A study following treatment choices rather than randomly assigning them; confounding can affect comparisons.

Off-label

Use outside a product’s authorized indication, route or schedule; it can be guideline-supported without becoming labeled use.

Oral

Swallowed, passing through the digestive system.

Perimenopause

The transition toward menopause, when periods and hormone patterns can change.

Placebo

A comparison treatment without the tested active medicine.

Postmenopause

The stage after menopause; context and other hormonal treatments matter when identifying it.

Progestogen

The broader family of progesterone-like medicines, including progesterone and synthetic progestins.

Randomized controlled trial

A study assigning participants to groups by chance to make a treatment comparison.

Sequential HRT

A regimen giving progestogen on selected days of a repeating cycle.

Systemic

Reaching the wider body through the circulation, rather than being intended mainly for a local site.

Transdermal

Absorbed through the skin, as with an estrogen patch; evidence for progesterone cream is different.

Vaginal

Administered in the vagina; the route alone does not establish systemic exposure or uterine protection.

Vasomotor symptoms

Hot flashes and night sweats.

Withdrawal bleeding

Bleeding following removal of hormonal exposure, such as after a sequential progesterone course.

Meningioma

A tumor arising from membranes around the brain and spinal cord; often benign, but its location can have serious effects.

How this guide was researched

We reviewed the current oral TU label, full ISSWSH guideline, current NICE recommendation and update history, UK female-cream SmPC, an original small randomized trial, a registered pilot proposal and the full 2026 bioequivalence paper. Study amounts remain investigational; no male dose is transferred into a female maintenance protocol. Source access levels and the registry’s unresolved operational status are explicit.

Public discussions identify questions about formulation, partial response and unwanted effects. They do not establish a verified female TU cohort or numerical satisfaction rate.; anatomical and route figures are conceptual, and research comparisons retain their population and duration.

Explore the sources